Objective-To identify transcriptomic biomarkers of coronary heart disease (CHD) in 188 cases with CHD and 188 age-and sex-matched controls who were participants in the Framingham Heart Study. Approach and Results-A total of 35 genes were differentially expressed in cases with CHD versus controls at false discovery rate<0.5, including GZMB, TMEM56, and GUK1. Cluster analysis revealed 3 gene clusters associated with CHD, 2 linked to increased erythrocyte production and a third to reduced natural killer and T cell activity in cases with CHD. Exon-level results corroborated and extended the gene-level results. Alternative splicing analysis suggested that GUK1 and 38 other genes were differentially spliced in cases with CHD versus controls. Gene Ontology analysis linked ubiquitination and T-cell-related pathways with CHD. Conclusions-Two bioinformatically defined groups of genes show consistent associations with CHD. Our findings are consistent with the hypotheses that hematopoesis is upregulated in CHD, possibly reflecting a compensatory mechanism, and that innate immune activity is disrupted in CHD or altered by its treatment. Transcriptomic signatures may be useful in identifying pathways associated with CHD and point toward novel therapeutic targets for its treatment and prevention. (Arterioscler Thromb Vasc
C oronary heart disease (CHD) is a leading cause of death in the United States 1 and the world. 2 In the United States alone, >16.3 million adults have CHD, and an estimated 935 000 heart attacks occur each year. 3 The estimated direct cost of CHD in 2010 was $272.5 billion, and it is projected to reach $818 billion by 2030. 4 Hence, innovative diagnostic strategies are needed to improve prevention and treatment of CHD and to limit its growing burden.
Recent research has indicated that CHD is influenced by environmental and genetic factors. 5, 6 Most genetic effects are modest in size, and the vast majority of the heritability of CHD remains unexplained. 7 Many of the known CHD susceptibility loci come from genome-wide association studies of common single nucleotide polymorphisms. [8] [9] [10] [11] [12] Another promising approach to identifying CHD biomarkers is from studies of gene expression signatures of CHD, [13] [14] [15] which have yielded promising results, but to date only a few genes are common across studies. More thorough gene expression studies of CHD are needed for new discoveries and to corroborate previous findings. 16 The Framingham Heart Study, a large observational study that has contributed to the identification and elucidation of risk factors for CHD, 17 recently launched the Systems Approach to Biomarker Research (SABRe) in cardiovascular disease initiative, a large-scale population-based study that seeks to discover, validate, and characterize biomarkers of atherosclerotic cardiovascular disease and its major risk factors. 18 SABRe resources include gene-and exon-level expressions, which can be used to understand biological underpinnings of multiple complex traits and diseases.
As part of SABRe, this investigation sought to identify and characterize gene expression signatures of CHD. To do so, we used an efficient CHD case-control design and assessed gene expression from RNA derived from whole blood using a commercial microarray. Analysis was conducted at the gene and exon levels, and we conducted a validation study using quantitative real-time polymerase chain reaction (qPCR). A search for alternative splicing signatures was performed. Hierarchical cluster analysis was performed to investigate pathways associated with CHD, and results were annotated with Gene Ontology (GO) and Gene Set Enrichment analyses. Across these analyses, we highlighted common pathways and genes. It is hoped that the identification of gene expression signatures of CHD will facilitate personalized approaches to the diagnosis, prevention, and treatment of this disease.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Study Sample Characteristics
The clinical characteristics of the study sample are provided in Table 1 . We investigated the extended pedigree structure of the participants and found that 3 extended families were heavily represented in the study sample, contributing a total of 36 participants (19 cases, 17 controls). To account for the possible bias resulting from inclusion of participants from the same extended families, we adjusted for pedigree in all the subsequent analyses, with the exception of the clustering analysis.
Technical Data Adjustment
Ten technical covariates fulfilled our selection criteria (Table I in the online-only Data Supplement). These technical covariates were used to adjust the data in all analyses.
Gene-Level Differential Expression
Gene-level results for differential expression in CHD cases versus controls are reported in Table 2 . At false discovery rate (FDR)<0.5, there were 35 genes. Twenty-six of these were found to be upregulated in CHD. GO enrichment analysis of the top 35 differentially expressed genes or of the 26 upregulated genes did not reveal any significantly enriched gene categories. GO analysis of the 9 downregulated genes detected a weak association with the category "induction of apoptosis by intracellular signals" (P=6.7E-4). Investigation using the Novartis GeneAtlas revealed that a large number of upregulated genes were specific to CD71 + early erythroid cells (TSTA3, CHPT1, FIS1, GABARAPL2, GUK1, and GYPB).
To better understand the biological themes within the data, the selection cutoff was relaxed to P<0.01, yielding 269 genes (Table II in the online-only Data Supplement) . GO analysis of the 164 upregulated genes revealed significant enrichment with hemoglobin complex genes (3 of 8, P=5. 3E-5) . A large number of genes were specific to CD71 + early erythroid cells. Analysis of 105 downregulated genes using Gene Set Enrichment analyses did not show strong GO enrichment, but did show significant overlap with the caspase cascade (P=8e-5) and extrinsic apoptosis (P=2E-5) genes (FASLG, GZMB, KLRD1, CASP8, RIPK1, and KIR2DL5A).
Adjusting for CHD risk factors (model 2) attenuated the P values of the top genes, but did not materially alter their ranking. All genes were differentially expressed between cases and controls by ≤1.4-fold, consistent with the small effect sizes found in previous studies. 13, 14 Among 478 genes that were reported to be associated with CHD in previous studies, 13, 14, [19] [20] [21] 59 had P<0.05 in our results (Tables III and IV  in 
Cluster Analysis
We next analyzed genes in groups using hierarchical cluster analysis, which allows aggregation of smaller effect sizes. This analysis should identify clusters of coherently expressed genes and, by averaging over clusters, allows detection of weaker associations with CHD.
Hierarchical cluster analysis divided all genes into 21 clusters, and for each a representative metagene was computed by averaging all genes across the cluster (Table V in -5) . The heatmap of these clusters can be found in Figure I in the online-only Data Supplement. The summary of differential expression t-statistic can be found in Figure 1 . The list of genes in these 3 clusters can be found in Table VI in the online-only Data Supplement.
Many of these clusters comprise genes that are specific to particular cell subpopulations using the Novartis Human Tissue Compendium. 22 The 32 genes in cluster 15 are nearly all specific to CD56 + natural killer cells but with some expression on peripheral blood CD4 + T cells and CD8 + T cells. Overall downregulation of genes in this cluster by 6% identified an immune component to CHD. The gene GZMB (cytotoxic T-lymphocyte-associated serine esterase) in this cluster was also the most strongly significant (P<0.0001) gene of any individual downregulated gene in our study. The protein product of this gene, granzyme B, has been associated with atherosclerosis 23 and increases plaque instability and risk of rupture by promoting apoptosis of macrophage foam cell. 23 Many of the 126 genes of cluster 21 are specifically expressed in CD71 + early erythroid cells. As a group, this cluster was significantly upregulated in CHD cases, on an average by 7%. Cluster 6, 
qPCR Validation of Differential Expression
Of the 93 genes assayed by qPCR (Table VIII in the onlineonly Data Supplement), 52 genes show positive, significant Spearman correlation coefficients (>0.5). Of these, 50 genes show directionally consistent FCs versus the microarray data. Nine genes, including 4 of the top differentially expressed genes (SGIP1, CCDC144A, GYPE, and DLEU2), were detected by PCR in <11 samples, and therefore were excluded from this analysis. Differential gene expression analysis using qPCR corroborated FCs measured by microarray (Figure 2 ). Many of these 50 genes exhibited larger FCs in qPCR data compared with microarray. This effective compression of FC by microarray is well documented.
24 P values from qPCR were generally weaker than those determined from microarray, in part, because fewer samples were available for qPCR. Nevertheless, 35 of the 52 genes were significantly differentially expressed in cases (P<0.05). Eight of these genes (TSTA3, HBM, GUK1, ZDHHC2, GZMB, GYPB, GABARAPL2, and TMEM56) were among the top gene-level results from microarray analyses (Table VIII in the online-only Data Supplement).
Exon-Level Differential Expression
Exon-level analysis (n=209 699) confirmed and extended the gene-level differential expression results (Table IX in the online-only Data Supplement). Two genes contain exons that were differentially expressed at FDR<0.1 (ABCC5 and MUC21); at FDR<0.5, a total of 2199 distinct genes contained significant exons, although some with only a single significant exon was identified. Twenty-nine of the top 35 genes in our gene-level results (Table 2) were also among these 2199 genes, with 23 of them represented by at least 2 exons (Table X in show averages strongly displaced from zero, with a large proportion of members, which are individually significant. Positive numbers are overexpressed in cases with coronary heart disease. The metagene (Methods) for these clusters and for cluster 6 are strongly significant, even after adjustment for multiple testing ( 24 with some genes also specific to cardiac myocytes. . Ninety-three genes were submitted for validation of all subjects. Of these, 52 genes showed positive Spearman correlation coefficients that were >0.5. Base 2 logarithmic fold changes (case/control) were computed for both technical covariate-adjusted microarray data (model 1) and RT-qPCR data. Fifty of 52 genes show fold changes with the same sign in both methods, although the qPCR data show changes of larger magnitude (above the line of identity in first quadrant). The sole downregulated gene (GZMB) shows a downward 1.14-fold change by microarray but a downward 1.27 change by qPCR. The largest upward fold change of 1.17 occurs in SLPI by microarray, but is found to be 1.4 when measured by qPCR. Table IX in the online-only Data Supplement). A subset of 470 genes was represented by ≥2 significant exons. Of these, 83 genes fell into clusters 6 and 21 and were exclusively upregulated. Eleven genes fell into cluster 15 and were exclusively downregulated. Of these, 3 were previously identified at the gene level (Table II in The results of exon-level GO enrichment analyses are summarized in Table XI in the online-only Data Supplement. GO enrichment of upregulated genes pointed to protein K48-linked ubiquitination (7 of 34 genes; P=1.2E-6), whereas downregulated genes pointed to leukocyte apoptosis and base-excision repair (4 of 40 and 4 of 33 genes, P=4.2E-4 and 2.0E-4, respectively).
Differential Alternative Splicing
Because we found many more differentially expressed genes at the exon level than at the gene level, we hypothesized that some of the additional genes actually display differential usage of splice variants. Accordingly, we performed differential alternative splicing analysis that yielded 6 genes at FDR<0.05 and 40 genes at FDR<0.5 (Tables XII and XIII in the online-only Data Supplement). The most significant differentially alternatively spliced gene, GUK1, is in cluster 21 and among the top 35 differentially expressed genes. For GUK1, the reduced differential expression at the first exon (probeset 2383862) may be the result of use of an alternative transcription start site, as suggested in the RefSeq collection of transcript isoforms. 25 
Validation of Differential Alternative Splicing
Two examples of alternative splicing detected by the exon array, where evidence for alternative exon usage coincided with that given in the RefSeq database, were studied by RNA-seq: GUK1, the top ranked alternatively spliced gene, and TMEM56, the third ranked gene. GUK1 has 3 alternative start sites, but the Affymetrix Exon array targeted only one of them (Exon1b, Figure 3A , probeset 23833862, Figure II in the online-only Data Supplement). This probeset showed a strong signal for differential alternative splicing (P<4E-9). RNA-seq data showed that all 3 start-sites are used. Viewing the individual gapped reads ( Figure II in the online-only Data Supplement) in the neighborhood of the first 2 start sites, we see that the exon targeted by the probeset is more commonly used, but a small fraction of reads map to the earlier start site, confirming the possibility for alternate start site usage. This RNA-seq information provides support for the potential differential alternative splicing between CHD cases and controls in our study.
The second example, TMEM56, also has 3 start sites, and again the first probeset, 2347744, which gives rise to the alternative splice signal, corresponds to the second start site (Exon 1b, Figure 3B , Figure III in the online-only Data Supplement). Unfortunately, the Affymetrix Exon Array does not provide probes for the first or third start sites. However, viewing the gapped reads for all 16 subjects reveals alternate usage of the second and third start sites, with 4 gapped reads mapping to the second site and 25 reads mapping to the third site ( Figure  III in the online-only Data Supplement). The overall expression level is too low to conclude whether the use of each start site differs among individuals, but both sites (exons) are used. This provides further support for alternative usage of start sites of TMEM56 and our evidence that alternative splicing of this gene differs in cases with CHD versus controls.
Discussion
We identified and characterized transcriptomic signatures and pathways (Tables 3 and 4 ) associated with CHD based on gene expression analysis of whole blood. Our study is one of several attempts to identify transcriptomic biomarkers of CHD, which may be helpful in understanding the pathobiology of CHD, in identifying robust risk markers of individuals at high risk for CHD, and in prioritizing novel therapeutic targets for treating the disease.
Although many of the effect sizes of differentially expressed genes were small, as found in previous studies, 14, 21 3 key findings emerged. First, many upregulated genes fall into clusters strongly associated with CD71 + early erythrocyte cells. Second, a cluster of genes associated with natural killer-cells is downregulated in CHD. Third, our results suggest that alternative splicing may play a role in CHD.
Many genes that were upregulated in CHD cases fall into cluster 21 or cluster 6, both strongly associated with CD71 + early erythrocyte cells. Association of elevated reticulocyte count with pulmonary and cardiac disease has been reported 26 and attributed to hypoxia-mediated erythropoietin production. Cluster 6 genes are also associated with the ubiquitination pathway (Table VI in the online-only Data Supplement). Gene SIAH2, in cluster 6, controls the ubiquitination of prolyl hydroxylase 1 and prolyl hydroxylase 3 during mild hypoxic conditions, and is 1 regulator of hypoxia-inducible factor 1-α. 27 Hypoxia-inducible factor 1-α mediates hypoxiainduced upregulation of GATA1 (also in cluster 6), which itself is essential to erythropoiesis. 28 Thus, CHD, or the ischemia associated with it, may upregulate hematopoiesis as a compensatory mechanism.
Cluster 15 contains many natural killer-and T-cellspecific genes, such as GZMB, and is downregulated in CHD. Paradoxically, plasma levels of granzyme B have been seen to increase after myocardial infarction. 29, 30 In any case, our observation may signal that perturbations of the innate immune system are involved in the pathogenesis of CHD or possibly are a result of its treatment. Other clusters also show interesting expression changes in cases versus controls, but do not reach the same degree of statistical significance. For example, the 61 genes in cluster 20 include many markers of platelets and are consistently, but not significantly, downregulated in CHD cases.
Our top gene findings suggest potentially important roles of ubiquitination and apoptosis pathways in CHD. SLC7A11 has been associated with ubiquitination, 31 may have widespread regulatory roles, 32, 33 and may play a role in cell apoptosis.
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SERPINB6, GUK1, HAGH, and USP28 are also associated with ubiquitination and may have widespread regulatory roles. 32, 33 ZDHHC2 may also have proapoptotic activity. 35 To follow up on the differential expression analyses, qPCR validation was conducted, and it confirmed several of the top genes from the microarray results, including TMEM56, ZDHHC2, and GUK1. In general, qPCR results were highly correlated with microarray expression and revealed greater FCs, but weaker P values than on microarray, partly attributable to the reduced sample size. Our results of differential expression confirmed only a relatively small number of the genes reported in previous coronary disease expression studies, 13, 14 including HBM, TMEM48, and PDGFD (Table III in the online-only Data Supplement). Of 14 genes reported to discriminate coronary artery stenosis from controls by Wingrove et al, 14 we could confirm only one, and only with modest significance (P=0.04). Differences in phenotypes, in the biological samples (peripheral blood mononuclear cells versus whole blood), and in the measurement platforms may account for the low degree of confirmation. For example, 1 gene, CSF2RA, was not measured on our platform. For 11 others, the direction of the effect we observed was zero or opposite to that previously reported. The gene association we did confirm, HK3, is specifically expressed in CD33 + myeloid cells and CD14 + monocytes. 22 It is partially transcriptionally regulated by hypoxia inducible factor signaling 36 and thus, may respond to the same signals that gave rise to upregulation of reticulocyte-specific cluster 21 and cluster 6 genes, although HK3 itself did not fall into those clusters. Three other genes reported by Wingrove (HBM, TFDP1, and KCTD15) had P<0.01 and the same effect direction in our results.
Exon-level results identified many of the same genes that emerged from gene level analyses and also pointed to apoptosis [37] [38] [39] and ubiquitination 40 in CHD. Apoptosis in the heart can be activated by cytokines, thereby increasing oxidative stress and DNA damage. 39 Ubiquitination is involved in many cellular processes. One of the systems that regulates ubiquitination is the ubiquitin-proteasome system. 41 Ubiquitin-proteasome system also maintains dynamic equilibrium of proteins and prevents accumulation of damaged and misfolded proteins that may contribute to CHD. 40 Our analysis identified 40 genes, including GUK1 and TMEM56, which may be alternatively spliced in relation to CHD status. Because alternative splicing analysis is prone to false positives, 42 especially when there are many predicted splice sites in a gene, 43 it is difficult to ascertain alternative splice events from statistical inference based on microarray data alone. To confirm and validate our results, we exploited the high-resolution RNA-seq technique, which can recognize individual splice-sites from the alignment of fragmentary sequences (reads). Validation of the alternative splicing hypothesis for 2 top genes was achieved. Alternative splicing of GUK1 produces 5 transcripts leading to 3 possible protein isoforms. Our analysis could distinguish the first transcript variant that produces only isoform b from the second, third, or fourth variants that produce isoforms b, c, or a, respectively. Thus, the observed alternative splicing could potentially have functional significance. Similarly, TMEM56 was found to be differentially alternatively spliced in cases with CHD versus controls. Here, we could distinguish between the second transcript variant of TMEM56 and a third, TMEM56-RWDD3, which represents naturally occurring read-through transcription between TMEM56 and the neighboring RWDD3 gene. But the functional significance of the distinct protein products of these 2 variants is unclear. However, TMEM56 was recently reported to have significant differential allelic distribution and differential expression in a genome-wide association studies of hypertension. 44 These authors also reported that the gene has a cis-expression quantitative trait locus at single nucleotide polymorphism rs11165334. Confirmation of the specific genes and differential alternative splicing patterns that we identified in cases with CHD versus controls will require external confirmation. The pathways were detected using Gene Ontology, or Gene Set Enrichment analyses, at a cutoff level of P<0.001. The pathways were then grouped based on the keywords in the first column. NK indicates natural killer. *Only when intersected with genes previously associated in the literature.
Study Strengths and Weaknesses
To our knowledge, this study is the largest CHD gene expression study to date using an exon-specific microarray. We used an efficient case-control experimental design with meticulous ascertainment of cases and careful accounting for technical covariates affecting expression. Because differential gene expression signals for CHD are weak, careful experimental design and quality control are important to improve the detection of differentially expressed genes. To reduce laboratory effects, we located each case and its corresponding control within the same batch of 96 samples. Although a few of the genes associated with CHD in previous studies were confirmed, the large majority were not. Inability to replicate gene associations with CHD may be attributable to multiple factors, including differences in the biological tissue sampled, RNA processing methods, microarray design, experimental design, and phenotypes. Our study analyzed prevalent CHD and not incident events. Thus, the observed gene signatures may be downstream of the disease process and not causally linked to its occurrence. Similarly, lipid, hypertension, and other treatment effects on expression may be powerful, and not fully accounted for by multivariate adjustment. Whole blood, the RNA source used in this experiment, comprises many different blood cell types, each of which may have a unique signature with respect to CHD. Such admixture of disparate signatures may obscure the detection of signals from any single cell type. Adjustment for CHD risk factors in our analyses (model 2) diminished the significance of many of the gene signals, suggesting that these signals may be partially mediated by established risk factors. Yet, the inclusion of CHD risk factors into the model did not significantly alter the rank of the top genes, suggesting that other factors, in conjunction with these risk factors, may drive the expression signatures we identified. Far larger sample sizes and collection of samples before the occurrence of CHD are needed to corroborate our findings and identify additional transcriptomic signals.
Our results are consistent with the hypothesis that CHD exhibits complex patterns of gene expression changes that are influenced by both environmental and CHD risk factors. 45 Because of the existence of such complex patterns, elucidation of the molecular mechanisms of CHD will require an integrative, systems approach. Such an approach is discussed in our companion article.
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Conclusions
We provide the results of complementary approaches that identified several transcriptomic signatures of CHD. We used hierarchical cluster analysis and found convergence of results with those from single gene differential expression. Additionally, our results suggest that alternative splicing differs between cases with CHD and controls, and we validated splice variation via RNA-seq in a separate study. Although several genes from previous studies were confirmed, the majority did not replicate. This underscores the need for further studies with larger sample sizes, careful experimental designs, and rigorous accounting for CHD risk factors and post-CHD treatment interventions. Such studies may contribute toward our understanding of CHD causal mechanisms and ultimately toward new approaches to the treatment and prevention of this disease. All microarray data used herein are available online in dbGaP (http://www.ncbi.nlm.nih.gov/gap) accession number phs000007.
